Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 136

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 136
---
 where the failure to be so true and correct in all respects, individually or in the aggregate, has not had or would not       
 reasonably be expected to have a Material Adverse Change (disregarding any materiality, “material” or “Material Adverse Change” qualification contained in any such representation or warranty), and (2) the Company has                                  
 delivered a certificate confirming same to the Purchaser, executed by an officer of the Company (without personal liability) addressed to the Purchaser and dated the Effective Date;                                                                     |

| (ii) | the Company shall have fulfilled or complied in all material respects with each of the covenants of the Company                                                                                                                                   
 contained in the Agreement to be fulfilled or complied with by it on or prior to the Effective Time, and the Company shall have delivered a certificate confirming same to the Purchaser, executed by an officer of the Company (without personal 
 liability) addressed to the Purchaser and dated the Effective Date;                                                                                                                                                                               |

| (iii) | no Proceeding shall be pending or threatened by any Governmental Entity in any jurisdiction that is reasonably                                                                                                                             
 likely to (i) cease trade, enjoin, prohibit, or impose any limitations, damages, or conditions on, the Purchaser’s ability to acquire, hold, or exercise full rights of ownership over, any Common Shares, including the right to vote the 
 Common Shares, or (ii) prohibit or enjoin the Company or the Purchaser from consummating the Arrangement;                                                                                                                                  |

| (iv) | there shall have not occurred a Material Adverse Change and the Company has delivered a certificate confirming                                      
 same to the Purchaser, executed by an officers of the Company (without personal liability) addressed to the Purchaser and dated the Effective Date; |

| (vi) | Dissent Rights have not been exercised with respect to more than 5% of the issued and outstanding Common 
 Shares;                                                                                                  |

| (vii) | the Closing Net Cash shall be greater than or equal to zero and, neither Purchaser, Parent nor any other person                                                                                                        
 on their behalf shall be required to make a payment under the Plan of Arrangement, except as Purchaser may be required to pay Fair Value to any Dissenting Shareholder in accordance with the Plan of Arrangement; and |

| (viii) | The Company shall have provided the Depositary with sufficient funds to satisfy the aggregate Distribution 
 payable by the Company to the Shareholders pursuant to the Agreement and the Plan of Arrangement.